Management Options for Persistent Postoperative Acromegaly

Neurosurgery Clinics of North America

Volumn 23, Issue 4, 2012, Pages 621-638

  Mathioudakis, Nestoras ^a   Salvatori, Roberto ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acromegaly; Dopamine agonists; Growth hormone adenoma; Persistent; Radiotherapy; Recurrent; Somatostatin analogues

Indexed keywords

ANGIOPEPTIN; BROMOCRIPTINE; CABERGOLINE; DOPAMINE RECEPTOR STIMULATING AGENT; OCTREOTIDE; PASIREOTIDE; PEGVISOMANT; PLACEBO; SOMATOSTATIN DERIVATIVE;

ABDOMINAL CRAMP; ACROMEGALY; BLOATING; CARDIOMYOPATHY; CHOLELITHIASIS; CLINICAL EFFECTIVENESS; CONSTIPATION; COST CONTROL; CYTOREDUCTIVE SURGERY; DIARRHEA; DIZZINESS; DRUG COST; DRUG DOSE ESCALATION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FLATULENCE; GALLSTONE; GASTROINTESTINAL SYMPTOM; HUMAN; INJECTION SITE PAIN; LIPOHYPERTROPHY; MONOTHERAPY; NAUSEA; NAUSEA AND VOMITING; NOSE OBSTRUCTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RADIATION RESPONSE; REVIEW; RISK MANAGEMENT; SIDE EFFECT; SKIN IRRITATION; STEREOTACTIC RADIOSURGERY; SURGICAL RISK; SWEATING; TREATMENT OUTCOME; TUMOR GROWTH; VALVULAR HEART DISEASE;

ACROMEGALY; COMBINED MODALITY THERAPY; HUMAN GROWTH HORMONE; HUMANS; PITUITARY NEOPLASMS; POSTOPERATIVE PERIOD;

EID: 84867122257     PISSN: 10423680     EISSN: 15581349     Source Type: Journal    
DOI: 10.1016/j.nec.2012.06.005     Document Type: Review

References (101)

1. Jane J.A., Starke R.M., Elzoghby M.A., et al. Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome. J Clin Endocrinol Metab 2011, 96:2732-2740.
2. Esposito V., Santoro A., Minniti G., et al. Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: outcome analysis in a series of 125 patients. Neurol Sci 2004, 25:251-256.
3. Reid T.J., Post K.D., Bruce J.N., et al. Features at diagnosis of 324 patients with acromegaly did not change from 1981 to 2006: acromegaly remains under-recognized and under-diagnosed. Clin Endocrinol (Oxf) 2010, 72:203-208.
4. Dekkers O.M., Biermasz N.R., Pereira A.M., et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008, 93:61-67.
5. Roelfsema F., Biermasz N.R., Pereira A.M. Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 2012, 15(1):71-83.
6. De P., Rees D.A., Davies N., et al. Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission. J Clin Endocrinol Metab 2003, 88:3567-3572.
7. Besser G.M., Burman P., Daly A.F. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol 2005, 153:187-193.
8. Daly A.F., Tichomirowa M.A., Petrossians P., et al. Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab 2010, 95:E373-E383.
9. Holdaway I.M., Bolland M.J., Gamble G.D. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 2008, 159:89-95.
10. Del Porto L.A., Liubinas S.V., Kaye A.H. Treatment of persistent and recurrent acromegaly. J Clin Neurosci 2011, 18:181-190.
11. Giustina A., Barkan A., Casanueva F.F., et al. Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 2000, 85:526-529.
12. Giustina A., Chanson P., Bronstein M.D., et al. A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010, 95:3141-3148.
13. Holdaway I.M., Rajasoorya R.C., Gamble G.D. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004, 89:667-674.
14. Wu T.E., Lin H.D., Lu R.A., et al. The role of insulin-like growth factor-1 and growth hormone in the mortality of patients with acromegaly after trans-sphenoidal surgery. Growth Horm IGF Res 2010, 20:411-415.
15. Boero L., Manavela M., Danilowicz K., et al. Comparison of two immunoassays in the determination of IGF-I levels and its correlation with oral glucose tolerance test (OGTT) and with clinical symptoms in acromegalic patients. Pituitary 2011, [Epub ahead of print].
16. Brzana J.A., Yedinak C.G., Delashaw J.B., et al. Discordant growth hormone and IGF-I levels post pituitary surgery in patients with acromegaly naive to medical therapy and radiation: what to follow, GH or IGF-I values?. Pituitary 2011, [Epub ahead of print].
17. Rubeck K.Z., Madsen M., Andreasen C.M., et al. Conventional and novel biomarkers of treatment outcome in patients with acromegaly: discordant results after somatostatin analog treatment compared with surgery. Eur J Endocrinol 2010, 163:717-726.
18. Katznelson L., Atkinson J.L., Cook D.M., et al. American association of clinical endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update: executive summary. Endocr Pract 2011, 17:636-646.
19. Clemmons D.R. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 2011, 57:555-559.
20. Feelders R.A., Bidlingmaier M., Strasburger C.J., et al. Postoperative evaluation of patients with acromegaly: clinical significance and timing of oral glucose tolerance testing and measurement of (free) insulin-like growth factor I, acid-labile subunit, and growth hormone-binding protein levels. J Clin Endocrinol Metab 2005, 90:6480-6489.
21. Kim E.H., Oh M.C., Lee E.J., et al. Predicting long term remission by measuring immediate postoperative growth hormone levels and oral glucose tolerance test in acromegaly. Neurosurgery 2012, 70(5):1106-1113.
22. Sherlock M., Ayuk J., Tomlinson J.W., et al. Mortality in patients with pituitary disease. Endocr Rev 2010, 31:301-342.
23. Yamada S., Fukuhara N., Oyama K., et al. Repeat transsphenoidal surgery for the treatment of remaining or recurring pituitary tumors in acromegaly. Neurosurgery 2010, 67:949-956.
24. Wang Y.Y., Higham C., Kearney T., et al. Acromegaly surgery in Manchester revisited-the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission. Clin Endocrinol 2012, 76(3):399-406.
25. Dusek T., Kastelan D., Melada A., et al. Clinical features and therapeutic outcomes of patients with acromegaly: single centre experience. J Endocrinol Invest 2011, 34(11):e382-e385.
26. Karaca Z., Tanriverdi F., Elbuken G., et al. Comparison of primary octreotide-lar and surgical treatment in newly diagnosed patients with acromegaly. Clin Endocrinol 2011, 75:678-684.
27. Nomikos P., Buchfelder M., Fahlbusch R. The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'. Eur J Endocrinol 2005, 152:379-387.
28. Kurosaki M., Luedecke D.K., Abe T. Effectiveness of secondary transnasal surgery in GH-secreting pituitary macroadenomas. Endocr J 2003, 50:635-642.
29. Alahmadi H., Dehdashti A.R., Gentili F. Endoscopic endonasal surgery in recurrent and residual pituitary adenomas after microscopic resection. World Neurosurg 2012, 77(3-4):540-547.
30. Long H., Beauregard H., Somma M., et al. Surgical outcome after repeated transsphenoidal surgery in acromegaly. J Neurosurg 1996, 85:239-247.
31. Freda P.U., Wardlaw S.L., Post K.D. Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly. J Neurosurg 1998, 89:353-358.
32. Abe T., Ludecke D.K. Recent results of secondary transnasal surgery for residual or recurring acromegaly. Neurosurgery 1998, 42:1013-1021. [discussion: 21-2].
33. Leach P., Abou-Zeid A.H., Kearney T., et al. Endoscopic transsphenoidal pituitary surgery: evidence of an operative learning curve. Neurosurgery 2010, 67:1205-1212.
34. Erturk E., Tuncel E., Kiyici S., et al. Outcome of surgery for acromegaly performed by different surgeons: importance of surgical experience. Pituitary 2005, 8:93-97.
35. Petrossians P., Borges-Martins L., Espinoza C., et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005, 152:61-66.
36. Colao A., Attanasio R., Pivonello R., et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006, 91:85-92.
37. Espinosa de los Monteros A.L., Gonzalez B., Vargas G., et al. Surgical reintervention in acromegaly: is it still worth trying?. Endocr Pract 2009, 15:431-437.
38. Berker M., Hazer D.B., Yucel T., et al. Complications of endoscopic surgery of the pituitary adenomas: analysis of 570 patients and review of the literature. Pituitary 2011, [Epub ahead of print].
39. Tutuncu Y., Berker D., Isik S., et al. Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly. Pituitary 2011, [Epub ahead of print].
40. Ayuk J., Stewart S.E., Stewart P.M., et al. Efficacy of sandostatin LAR (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy. Clin Endocrinol 2004, 60:375-381.
41. Freda P.U., Katznelson L., van der Lely A.J., et al. Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. J Clin Endocrinol Metab 2005, 90:4465-4473.
42. Mazziotti G., Giustina A. Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 2010, 13:60-67.
43. Colao A., Pivonello R., Di Somma C., et al. Medical therapy of pituitary adenomas: effects on tumor shrinkage. Rev Endocr Metab Disord 2009, 10:111-123.
44. Yetkin D.O., Boysan S.N., Tiryakioglu O., et al. Forty month follow-up of persistent and difficultly controlled acromegalic patients treated with depot long acting somatostatin analog octreotide. Endocr J 2007, 54:459-464.
45. Caron P., Bex M., Cullen D.R., et al. One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clin Endocrinol 2004, 60:734-740.
46. Sherlock M., Fernandez-Rodriguez E., Alonso A.A., et al. Medical therapy in patients with acromegaly: predictors of response and comparison of efficacy of dopamine agonists and somatostatin analogues. J Clin Endocrinol Metab 2009, 94:1255-1263.
47. Puig-Domingo M., Resmini E., Gomez-Anson B., et al. Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab 2010, 95:4973-4978.
48. Bhayana S., Booth G.L., Asa S.L., et al. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 2005, 90:6290-6295.
49. Fleseriu M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 2011, 14:184-193.
50. Wuster C., Both S., Cordes U., et al. Primary treatment of acromegaly with high-dose lanreotide: a case series. J Med Case Rep 2010, 4:85.
51. Ludlam W.H., Anthony L. Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors. Adv Ther 2011, 28:825-841.
52. Salvatori R., Nachtigall L.B., Cook D.M., et al. Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in lanreotide-naive patients with acromegaly. Pituitary 2010, 13:96-102.
53. Tzanela M., Vassiliadi D.A., Gavalas N., et al. Glucose homeostasis in patients with acromegaly treated with surgery or somatostatin analogues. Clin Endocrinol 2011, 75:96-102.
54. Mazziotti G., Floriani I., Bonadonna S., et al. Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 2009, 94:1500-1508.
55. De Marinis L., Bianchi A., Fusco A., et al. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary 2007, 10:227-232.
56. Sandret L., Maison P., Chanson P. Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 2011, 96:1327-1335.
57. Mancini T., Casanueva F.F., Giustina A. Hyperprolactinemia and prolactinomas. Endocrinol Metab Clin North Am 2008, 37:67-99. viii.
58. Giustina A., Bronstein M.D., Casanueva F.F., et al. Current management practices for acromegaly: an international survey. Pituitary 2011, 14:125-133.
59. Feenstra J., de Herder W.W., ten Have S.M., et al. Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly. Lancet 2005, 365:1644-1646.
60. van der Lely A.J., Hutson R.K., Trainer P.J., et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001, 358:1754-1759.
61. Trainer P.J. ACROSTUDY: the first 5 years. Eur J Endocrinol 2009, 161(Suppl 1):S19-S24.
62. Trainer P.J., Ezzat S., D'Souza G.A., et al. Arandomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol 2009, 71:549-557.
63. van der Lely A.J., Bernabeu I., Cap J., et al. Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 2011, 164:325-333.
64. Neggers S.J., van der Lely A.J. Combination treatment with somatostatin analogues and pegvisomant in acromegaly. Growth Horm IGF Res 2011, 21:129-133.
65. Barkan A.L., Burman P., Clemmons D.R., et al. Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to pegvisomant. J Clin Endocrinol Metab 2005, 90:5684-5691.
66. Higham C.E., Atkinson A.B., Aylwin S., et al. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab 2012, 97(4):1187-1193.
67. Neggers S.J., van Aken M.O., de Herder W.W., et al. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant. J Clin Endocrinol Metab 2008, 93:3853-3859.
68. Katznelson L., Atkinson J.L., Cook D.M., et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly-2011 update. Endocr Pract 2011, 17(Suppl 4):1-44.
69. Brue T. ACROSTUDY: status update on 469 patients. Horm Res 2009, 71(Suppl 1):34-38.
70. Wilson C. Pharmacotherapy: pasireotide shows promise for the treatment of acromegaly. Nat Rev Endocrinol 2010, 6:417.
71. van der Hoek J., de Herder W.W., Feelders R.A., et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients. J Clin Endocrinol Metab 2004, 89:638-645.
72. Yang I., Kim W., De Salles A., et al. A systematic analysis of disease control in acromegaly treated with radiosurgery. Neurosurg Focus 2010, 29:E13.
73. Stapleton C.J., Liu C.Y., Weiss M.H. The role of stereotactic radiosurgery in the multimodal management of growth hormone-secreting pituitary adenomas. Neurosurg Focus 2010, 29:E11.
74. Shimon I., Cohen Z.R., Ram Z., et al. Transsphenoidal surgery for acromegaly: endocrinological follow-up of 98 patients. Neurosurgery 2001, 48:1239-1243. [discussion: 44-5].
75. Lancranjan I., Atkinson A.B. Results of a European multicentre study with Sandostatin LAR in acromegalic patients. Sandostatin LAR Group. Pituitary 1999, 1:105-114.
76. Chanson P., Boerlin V., Ajzenberg C., et al. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly. Clin Endocrinol 2000, 53:577-586.
77. Colao A., Ferone D., Marzullo P., et al. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly. J Clin Endocrinol Metab 2001, 86:2779-2786.
78. Ayuk J., Stewart S.E., Stewart P.M., et al. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 2002, 87:4142-4146.
79. Alexopoulou O., Abrams P., Verhelst J., et al. Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. Eur J Endocrinol 2004, 151:317-324.
80. Jallad R.S., Musolino N.R., Salgado L.R., et al. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution. Clin Endocrinol 2005, 63:168-175.
81. Grottoli S., Celleno R., Gasco V., et al. Efficacy and safety of 48 weeks of treatment with octreotide LAR in newly diagnosed acromegalic patients with macroadenomas: an open-label, multicenter, non-comparative study. J Endocrinol Invest 2005, 28:978-983.
82. Trepp R., Stettler C., Zwahlen M., et al. Treatment outcomes and mortality of 94 patients with acromegaly. Acta Neurochir (Wien) 2005, 147:243-251. [discussion: 50-1].
83. Cozzi R., Montini M., Attanasio R., et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab 2006, 91:1397-1403.
84. Colao A., Pivonello R., Rosato F., et al. First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial. Clin Endocrinol 2006, 64:342-351.
85. Ronchi C.L., Boschetti M., Degli Uberti E.C., et al. Efficacy of a slow-release formulation of lanreotide (Autogel) 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR): an open, multicentre longitudinal study. Clin Endocrinol 2007, 67:512-519.
86. Maiza J.C., Vezzosi D., Matta M., et al. Long-term (up to 18 years) effects on GH/IGF-I hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol 2007, 67:282-289.
87. Mercado M., Borges F., Bouterfa H., et al. A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly. Clin Endocrinol 2007, 66:859-868.
88. Colao A., Pivonello R., Auriemma R.S., et al. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007, 157:579-587.
89. Auriemma R.S., Pivonello R., Galdiero M., et al. Octreotide-LAR vs lanreotide-SR as first-line therapy for acromegaly: a retrospective, comparative, head-to-head study. J Endocrinol Invest 2008, 31:956-965.
90. Colao A., Cappabianca P., Caron P., et al. Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study. Clin Endocrinol 2009, 70:757-768.
91. Baldys-Waligorska A., Golkowski F., Krzentowska A., et al. Przegl Lek 2009, 66:218-221. [in Polish].
92. Oki Y., Inoue T., Imura M., et al. Investigation into the efficacy and safety of octreotide LAR in Japanese patients with acromegaly: Shizuoka study. Endocr J 2009, 56:1095-1101.
93. Luque-Ramirez M., Portoles G.R., Varela C., et al. The efficacy of octreotide LAR as firstline therapy for patients with newly diagnosed acromegaly is independent of tumor extension: predictive factors of tumor and biochemical response. Horm Metab Res 2010, 42:38-44.
94. Caron P., Beckers A., Cullen D.R., et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. J Clin Endocrinol Metab 2002, 87:99-104.
95. Caron P., Cogne M., Raingeard I., et al. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol 2006, 64:209-214.
96. Lucas T., Astorga R. Efficacy of lanreotide Autogel administered every 4-8 weeks in patients with acromegaly previously responsive to lanreotide microparticles 30 mg: a phase III trial. Clin Endocrinol 2006, 65:320-326.
97. Chanson P., Borson-Chazot F., Kuhn J.M., et al. Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48 weeks in patients with acromegaly. Clin Endocrinol 2008, 69:299-305.
98. Melmed S., Cook D., Schopohl J., et al. Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension. Pituitary 2010, 13:18-28.
99. Lombardi G., Minuto F., Tamburrano G., et al. Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly. J Endocrinol Invest 2009, 32:202-209.
100. Attanasio R., Lanzi R., Losa M., et al. Effects of lanreotide Autogel on growth hormone, insulinlike growth factor 1, and tumor size in acromegaly: a 1-year prospective multicenter study. Endocr Pract 2008, 14:846-855.
101. Schopohl J., Strasburger C.J., Caird D., et al. Efficacy and acceptability of lanreotide Autogel(R) 120 mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR. Exp Clin Endocrinol Diabetes 2011, 119:156-162.